HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) with a maintained price target of $4.5.
March 14, 2024 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Unicycive Therapeutics with a maintained price target of $4.5.
The reiteration of a Buy rating and maintenance of a $4.5 price target by a reputable analyst could positively influence investor sentiment and potentially lead to a short-term increase in UNCY's stock price. The analyst's bullish stance suggests confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100